Havish Thatavarthi, Volunteer at Oncology and Neuro Ward Nurse Assistant, shared an update from Yan Leyfman, Executive Committee Member at Music Beats Cancer, on LinkedIn, adding:
“The treatment landscape for chronic myeloid leukemia has transformed dramatically over the past two decades, and it continues to evolve.
In this episode, presented by MedNews Week: OncoDaily, Jorge Eduardo Cortes, Chief of Hematology at the University of Alabama at Birmingham and Deputy Director of the O’Neal Comprehensive Cancer Center at UAB, explores the evolution of CML treatment and the modern algorithms guiding care.
Key takeaways:
- How CML treatment has evolved from imatinib to second-generation tyrosine kinase inhibitors and asciminib, expanding treatment options while making therapy selection increasingly complex
- How molecular response, treatment-free remission, resistance mutations, safety, tolerability, and quality of life influence personalized treatment selection and sequencing
- How emerging therapies, dynamic dosing strategies, and artificial intelligence may help predict treatment response, personalize molecular monitoring, and shape the future definition of a cure in CML
This episode offers an important perspective for hematologists, oncologists, researchers, students, trainees, and patient advocates working to advance leukemia research and care.
Watch the full episode.
Through this episode, we aim to raise awareness, encourage collaboration, and inspire meaningful contributions to the future of cancer research and care.
Watch the episode, share your perspective, and join the conversation.”
Quoting Yan Leyfman:
“CML has changed. Have our treatment algorithms kept up?
The era of simply choosing a TKI and monitoring response is behind us.
Today, treating chronic myeloid leukemia means navigating an increasingly complex set of decisions:
Which TKI should you start – and for whom? When should an inadequate response trigger a switch? How should resistance mutations change treatment selection? Where do newer agents fit into sequencing? Who can safely pursue treatment-free remission – and when?
At this week’s MedNews Week Keynote Conference, we go directly into these questions with Dr. Jorge Eduardo Cortes, one of the investigators who helped build the evidence base behind modern CML therapy.
THE CML EVOLUTION: Mastering Modern Algorithms in Chronic Myeloid Leukemia
Dr. Cortes breaks down how CML management has evolved and, more importantly, how to translate that evolution into real-world treatment decisions at the bedside.
Now at the University of Alabama at Birmingham, Dr. Cortes has led 90+ Phase I–III clinical trials, authored 1,000+ scientific publications, abstracts, and academic contributions, and held major international leadership roles in CML-including leadership of the International Chronic Myeloid Leukemia Foundation.
This isn’t just a review of CML.
It is an opportunity to learn how one of the field’s most influential investigators thinks through the decisions that define modern CML care.
September 16, 2026 , 12:30 PM ET
MedNews Week Keynote Conference
Catch this episode exclusively on OncoDaily TV.
From first-line therapy – resistance – sequencing – treatment-free remission.
If you treat leukemia-or are training to-this is one conversation worth hearing.
MedNews Week: Connecting Medicine Globally.”
You might be interested in:
Treatment-Free Remission (TFR) in CML: Who, When, and How?
